The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

MK-677 / Ibutamoren

Research chemical · Grade C

Goals
muscle, sleep
Evidence
5 RCT / 0 animal / 0 in vitro
Routes
oral
WADA
S2
FDA
Not approved
Cancer caution
hard-stop
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

CJC-1295 (no-DAC)

Research chemical · Grade C

Goals
muscle, sleep
Evidence
—
Routes
injectable-sc
WADA
S2
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
These four changes extend the plasma half-life from 4-7 minutes to approximately 30 minutes without meaningfully changing GHRH receptor binding affinity
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

GHRP-2

Research chemical · Grade C

Goals
muscle, sleep
Evidence
—
Routes
injectable-sc
WADA
S2
FDA
Not approved
Cancer caution
hard-stop
Typical dose
—
Half-life
Plasma half-life: approximately 15-30 minutes following subcutaneous injection
Primary mechanism
GHS-R1a agonism on pituitary somatotrophs → Gq/11 → PLC → IP3 + DAG → intracellular calcium release → PKC activation → GH vesicle exocytosis.
View full report →

Ipamorelin

Research chemical · Grade C

Goals
muscle, sleep
Evidence
3 RCT / 0 animal / 0 in vitro
Routes
injectable-sc
WADA
S2
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
Plasma half-life approximately 2 hours — longer than GHRP-6 (~30 min distribution phase) due to the structural features providing protease resistance
Primary mechanism
GHS-R1a (ghrelin receptor) agonist: Gq-protein coupled → PLC-IP3-Ca²⁺ pathway → GH granule exocytosis from pituitary somatotrophs.
View full report →